Utility of drug-eluting stents in complex lesions and high-risk patients


Opinion statement

Drug-eluting stents represent a breakthrough technology designed to deliver high concentrations of a bioactive agent locally to an atherosclerotic lesion, thereby minimizing systemic side effects of the drug. The safety and efficacy of drug-eluting stents have clearly been demonstrated in noncomplex lesions. This article presents an evidence-based analysis of the current experience with CYPHER sirolimus-eluting stents (Cordis Corp., Miami Lakes, FL) and TAXUS paclitaxel-eluting stents (Boston Scientific, Natick, MA) in a broad spectrum of high-risk and/or complex subsets of patients and lesions, including those with diabetes mellitus, multivessel disease, diffuse disease, very small vessels, lesions in saphenous vein grafts, chronic total occlusions, in-stent restenosis, ostial and bifurcation lesions, unprotected left main disease, and acute myocardial infarction. Emerging data in several of these subsets suggest that drug-eluting stents are safe and effective, and their use may currently be recommended, whereas in other groups of patients and lesions the efficacy and/or safety of drug-eluting stents remains to be determined, thus warranting caution. It is anticipated that penetration of drug-eluting stents will continue to increase, and fewer patients will require surgical revascularization to achieve sustained event-free survival.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Morice MC, Serruys PW, Sousa JE, et al.: Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773–1780.PubMedCrossRefGoogle Scholar
  2. 2.
    Colombo A, Drzewiecki J, Banning A, et al.: Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108:788–794.PubMedCrossRefGoogle Scholar
  3. 3.
    Moses JW, Leon MB, Popma JJ, et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315–1323.PubMedCrossRefGoogle Scholar
  4. 4.
    Stone GW, Ellis SG, Cox DA, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221–231.PubMedCrossRefGoogle Scholar
  5. 5.
    Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [no authors listed]. N Engl J Med 1996, 335:217–225.Google Scholar
  6. 6.
    Stein B, Weintraub WS, Gebhart SP, et al.: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995, 91:979–989.PubMedGoogle Scholar
  7. 7.
    Abizaid A, Costa MA, Centemero M, et al.: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Circulation 2001, 104:533–538.PubMedCrossRefGoogle Scholar
  8. 8.
    Niles NW, McGrath PD, Malenka D, et al.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J Am Coll Cardiol 2001, 37:1008–1015.PubMedCrossRefGoogle Scholar
  9. 9.
    Moussa I, Leon MB, Baim DS, et al.: Impact of sirolimuseluting stents on outcome in diabetic patients: a SIRIUS (SIRolIm US-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004, 109:2273–2278.PubMedCrossRefGoogle Scholar
  10. 10.
    Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, et al.: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients. The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. Circulation 2005, 112:2175–2183.PubMedCrossRefGoogle Scholar
  11. 11.
    Hermiller JB, Raizner A, Cannon L, et al.: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005, 45:1172–1179.PubMedCrossRefGoogle Scholar
  12. 12.
    Dibra A, Kastrati A, Mehilli J, et al.: Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005, 353:663–670.PubMedCrossRefGoogle Scholar
  13. 13.
    Windecker S, Remondino A, Eberli FR, et al.: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005, 353:653–662.PubMedCrossRefGoogle Scholar
  14. 14.
    Morice MC: REALITY: Prospective, Randomized, Multicenter Head-to-Head Comparison of Cypher and Taxus Stent Systems. Paper presented at the American College of Cardiology 2005 Annual Scientific Session. Orlando, FL; March 6–9, 2005.Google Scholar
  15. 15.
    Cosgrave J, Agostoni P, Ge L, et al.: Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 2005, 96:1663–1668.PubMedCrossRefGoogle Scholar
  16. 16.
    Ong AT, Aoki J, van Mieghem CA, et al.: Comparison of short-(one month) and long-(twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005, 96:358–362.PubMedCrossRefGoogle Scholar
  17. 17.
    Doucet S, Schalij MJ, Vrolix MC, et al.: Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001, 104:2029–2033.PubMedGoogle Scholar
  18. 18.
    Hausleiter J, Kastrati A, Mehilli J, et al.: Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial. Am J Cardiol 2002, 89:58–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Nikolsky E, Moses JW, Cambier P, et al.: Results from the 2.25 mm Sirolimus-Eluting BX VelocityTM Stent Registry in patients with native coronary artery lesions. Transcatheter Cardiovascular Therapeutics, Washington, September 2005. Am J Cardiol 2005, 96(suppl 7):456.Google Scholar
  20. 20.
    Schofer J, Schluter M, Gershlick AH, et al.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003, 362:1093–1099.PubMedCrossRefGoogle Scholar
  21. 21.
    Schampaert E, Cohen EA, Schluter M, et al.: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004, 43:1110–1115.PubMedCrossRefGoogle Scholar
  22. 22.
    Sousa JE: SVELTE: Study in Patients with De Novo Coronary Artery Lesions in Small Vessels Treated With the Cypher Stent. Paper presented at the EuroPCR 2004, the Paris Course on Revascularization. Paris, France: May 25–28, 2004.Google Scholar
  23. 23.
    Ardissino D, Cavallini C, Bramucci E, et al.: Sirolimuseluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004, 292:2727–2734.PubMedCrossRefGoogle Scholar
  24. 24.
    Mehilli J, Dibra A, Kastrati A, et al.: Randomized trial of paclitaxel-and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006, 27:260–266.PubMedCrossRefGoogle Scholar
  25. 25.
    Stone GW, Ellis SG, Cannon L, et al.: Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005, 294:1215–1223.PubMedCrossRefGoogle Scholar
  26. 26.
    Tsagalou E, Chieffo A, Iakovou I, et al.: Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005, 45:1570–1573.PubMedCrossRefGoogle Scholar
  27. 27.
    Dawkins KD, Grube E, Guagliumi G, et al.: Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005, 112:3306–3313.PubMedCrossRefGoogle Scholar
  28. 28.
    Buller CE, Dzavik V, Carere RG, et al.: Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999, 100:236–242.PubMedGoogle Scholar
  29. 29.
    Hoher M, Wohrle J, Grebe OC, et al.: A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol 1999, 34:722–729.PubMedCrossRefGoogle Scholar
  30. 30.
    Lotan C, Rozenman Y, Hendler A, et al.: Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur Heart J 2000, 21:1960–1966.PubMedCrossRefGoogle Scholar
  31. 31.
    Rahel BM, Suttorp MJ, Laarman GJ, et al.: Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Am Heart J 2004, 147:e22.PubMedCrossRefGoogle Scholar
  32. 32.
    Stone GW, Kandzari DE, Mehran R, et al.: Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 2005, 112:2364–2372.PubMedCrossRefGoogle Scholar
  33. 33.
    Stone GW, Reifart NJ, Moussa I, et al.: Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005, 112:2530–2537.PubMedCrossRefGoogle Scholar
  34. 34.
    Suttorp MJ: Prospective Randomized Trial of Sirolimus-Eluting and Bare Metal Stents in Patients with Chronic Total Occlusions. (PRISON II). Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington, DC; October 16–21, 2005.Google Scholar
  35. 35.
    Werner GS, Schwarz G, Prochnau D, et al.: Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc Interv 2006, 67:1–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Lefevre T, Louvard Y, Morice MC, et al.: Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv 2000, 49:274–283.PubMedCrossRefGoogle Scholar
  37. 37.
    Al Suwaidi J, Yeh W, Cohen HA, et al.: Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001, 87:1139–1144.PubMedCrossRefGoogle Scholar
  38. 38.
    Colombo A: Balloon crush: new tool in bifurcation treatment armamentarium. Catheter Cardiovasc Interv 2004, 63:417–418.PubMedCrossRefGoogle Scholar
  39. 39.
    Colombo A, Moses JW, Morice MC, et al.: Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004, 109:1244–1249.PubMedCrossRefGoogle Scholar
  40. 40.
    Pan M, de Lezo JS, Medina A, et al.: Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J 2004, 148:857–864.PubMedCrossRefGoogle Scholar
  41. 41.
    Tanabe K, Hoye A, Lemos PA, et al.: Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 2004, 94:115–118.PubMedCrossRefGoogle Scholar
  42. 42.
    Ge L, Airoldi F, Iakovou I, et al.: Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. Am Coll Cardiol 2005, 46:613–620.CrossRefGoogle Scholar
  43. 43.
    Mercado N, Wijns W, Serruys PW, et al.: One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 2005, 130:512–519.PubMedCrossRefGoogle Scholar
  44. 44.
    Serruys PW, Unger F, Sousa JE, et al.: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001, 344:1117–1124.PubMedCrossRefGoogle Scholar
  45. 45.
    Schonberger JP, Buller N, Bonser R, et al.: Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005, 46:575–581.PubMedCrossRefGoogle Scholar
  46. 46.
    Serruys PW, Lemos PA, van Hout BA: Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 2004, 90:995–998.PubMedCrossRefGoogle Scholar
  47. 47.
    Mikhail GW, Airoldi F, Tavano D, et al.: The use of drug eluting stents in single and multivessel disease: results from a single centre experience. Heart 2004, 90:990–994.PubMedCrossRefGoogle Scholar
  48. 48.
    Park SJ, Kim YH, Lee BK, et al.: Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005, 45:351–356.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee SH, Ko YG, Jang Y, et al.: Sirolimus-versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis. Cardiology 2005, 104:181–185.PubMedCrossRefGoogle Scholar
  50. 50.
    Valgimigli M, van Mieghem CA, Ong AT, et al.: Short-and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005, 111:1383–1389.PubMedCrossRefGoogle Scholar
  51. 51.
    Chieffo A, Stankovic G, Bonizzoni E, et al.: Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005, 111:791–795.PubMedCrossRefGoogle Scholar
  52. 52.
    de Lezo JS, Medina A, Pan M, et al.: Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J 2004, 148:481–485.PubMedCrossRefGoogle Scholar
  53. 53.
    Gershlick A, Guagliumi G, Guyon P, et al.: Sirolimus eluting stent and unprotected left main stenosis: the multicenter e-cypher registry [abstract]. Heart 2005, 91:a5–i72.Google Scholar
  54. 54.
    Lee MS, Kapoor N, Jamal F, et al.: Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006, 47:864–870.PubMedCrossRefGoogle Scholar
  55. 55.
    Price MJ, Cristea E, Sawhney N, et al.: Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol 2006, 47:871–877.PubMedCrossRefGoogle Scholar
  56. 56.
    Buszman P: Acute and late outcome of unprotected left main stenting in comparison with surgical revascularization. The LE MANS trial. Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington, DC; October 16–21, 2005.Google Scholar
  57. 57.
    Teirstein PS, Massullo V, Jani S, et al.: Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000, 101:360–365.PubMedGoogle Scholar
  58. 58.
    Waksman R, White RL, Chan RC, et al.: Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000, 101:2165–2171.PubMedGoogle Scholar
  59. 59.
    Waksman R, Cheneau E, Ajani AE, et al.: Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation 2003, 107:1744–1749.PubMedCrossRefGoogle Scholar
  60. 60.
    Leon MB, Teirstein PS, Moses JW, et al.: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001, 344:250–256.PubMedCrossRefGoogle Scholar
  61. 61.
    Neumann FJ, Desmet W, Grube E, et al.: Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005, 111:2107–2111.PubMedCrossRefGoogle Scholar
  62. 62.
    Tanabe K, Serruys PW, Grube E, et al.: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003, 107:559–564.PubMedCrossRefGoogle Scholar
  63. 63.
    Alfonso F, Angel J, Cequier A, et al.: Results of the restenosis intrastent: balloon angioplasty versus rapamycin-eluting stent implantation randomized study [abstract]. J Am Coll Cardiol 2005, 45:83A.Google Scholar
  64. 64.
    Kastrati A, Mehilli J, von Beckerath N, et al.: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005, 293:165–171.PubMedCrossRefGoogle Scholar
  65. 65.
    Holmes DR: Sirolimus-Eluting Stent vs. Brachytherapy in Patients With Bare Metal In-Stent Restenosis (SISR). Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington, DC; October 16–21, 2005.Google Scholar
  66. 66.
    Stone GW, Ellis SG, O’shaughnessy CD, et al.: Paclitaxeleluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents. The TAXUS V ISR randomized trial. JAMA 2006, 295:1253–1263.PubMedCrossRefGoogle Scholar
  67. 67.
    Waskman R: How to manage drug-eluting stent in-stent restenosis. Paper presented at the the EuroPCR 2005. Paris, France; May 24–27, 2005.Google Scholar
  68. 68.
    Cheneau E, John MC, Fournadjiev J, et al.: Time course of stent endothelialization after intravascular radiation therapy in rabbit iliac arteries. Circulation 2003, 107:2153–2158.PubMedCrossRefGoogle Scholar
  69. 69.
    de Jaegere PP, van Domburg RT, Feyter PJ, et al.: Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996, 28:89–96.PubMedCrossRefGoogle Scholar
  70. 70.
    Savage MP, Douglas JS Jr, Fischman DL, et al.: Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997, 337:740–747.PubMedCrossRefGoogle Scholar
  71. 71.
    Hoye A, Lemos PA, Arampatzis CA, et al.: Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004, 16:230–233.PubMedGoogle Scholar
  72. 72.
    Ge L, Iakovou I, Sangiorgi GM, et al.: Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005, 45:989–994.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee MS, Shah AP, Aragon J, et al.: Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005, 66:507–511.PubMedCrossRefGoogle Scholar
  74. 74.
    Chu WW, Rha SW, Kuchulakanti PK, et al.: Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006, 97:34–37.PubMedCrossRefGoogle Scholar
  75. 75.
    Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Stone GW, Grines CL, Cox DA, et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957–966.PubMedCrossRefGoogle Scholar
  77. 77.
    Lemos PA, Saia F, Hofma SH, et al.: Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004, 43:704–708.PubMedCrossRefGoogle Scholar
  78. 78.
    Valgimigli M, Percoco G, Malagutti P, et al.: Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005, 293:2109–2117.PubMedCrossRefGoogle Scholar
  79. 79.
    Grines CL, Cox DA, Stone GW, et al.: Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999, 341:1949–1956.PubMedCrossRefGoogle Scholar
  80. 80.
    Laarman GJ: PASSION: Primary PCI is the most effective reperfusion therapy for acute myocardial infarction. Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington DC; October 16–21, 2005.Google Scholar
  81. 81.
    Kernis SJ, Cohen D, Reid K, et al.: Clinical outcomes associated with drug-eluting stents compared with bare-metal stents for primary percutaneous intervention [abstract]. Am J Cardiol 2005, 96:47H.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Herbert Irving PavilionColumbia University Medical CenterNew YorkUSA

Personalised recommendations